GlassScriptPhysician profile
Fatima Rizwan Khalid
NPI 1710273685
$1,674.66
in general payments reported to CMS, 2019-2025
20 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $352 · 2023: $369 · 2024: $567 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229 · Education: $92.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.36 |
| Education | $92.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $763.75 | 2022-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $257.53 | 2022-2025 | Envarsus |
| Glaxosmithkline, LLC. | $112.22 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $73.83 | 2022-2025 | Ultomiris |
| Amgen INC. | $64.76 | 2025 | Krystexxa, Tavneos |
| Novo Nordisk INC | $53.34 | 2022-2025 | Ozempic |
| Cormedix INC. | $45.27 | 2024-2025 | Defencath, Defencath |
| Abbott Laboratories | $40.23 | 2022 | |
| Calliditas Therapeutics US INC. | $33.69 | 2025 | Tarpeyo |
| Nxstage Medical, INC. | $31.72 | 2022-2023 | Nxstage Pureflow Solution, Nxstage System One |
| Horizon Therapeutics Plc | $25.65 | 2023 | Krystexxa |
| Recor Medical INC | $25.26 | 2024 | Paradise Renal Denervation System |
| Opko Pharmaceuticals, LLC | $23.17 | 2024 | Rayaldee |
| Travere Therapeutics, INC. | $21.30 | 2023-2025 | |
| Chiesi USA, INC. | $20.56 | 2025 | Elfabrio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.13 | 2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $16.99 | 2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $16.88 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.39 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.